SK Biopharmaceuticals Co., Ltd. (326030.KS)
KRW 103600.0
(-2.54%)
KRW 103600.0
(-2.54%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 178.05 Billion KRW | 14.21% |
| 2022 | 155.89 Billion KRW | 890.6% |
| 2021 | 15.73 Billion KRW | -14.83% |
| 2020 | 18.47 Billion KRW | -83.06% |
| 2019 | 109.05 Billion KRW | 0.0% |
| 2018 | - KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| 2011 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 206.23 Billion KRW | 0.64% |
| 2024 Q1 | 204.91 Billion KRW | 15.09% |
| 2023 Q1 | 156.44 Billion KRW | 0.35% |
| 2023 Q2 | 155.63 Billion KRW | -0.51% |
| 2023 Q3 | 180.94 Billion KRW | 16.26% |
| 2023 Q4 | 178.05 Billion KRW | -1.6% |
| 2023 FY | 178.05 Billion KRW | 14.21% |
| 2022 Q2 | 58.88 Billion KRW | 4.48% |
| 2022 FY | 155.89 Billion KRW | 890.6% |
| 2022 Q4 | 155.89 Billion KRW | -4.32% |
| 2022 Q3 | 162.94 Billion KRW | 176.7% |
| 2022 Q1 | 56.36 Billion KRW | 258.15% |
| 2021 FY | 15.73 Billion KRW | -14.83% |
| 2021 Q3 | 17.06 Billion KRW | -5.62% |
| 2021 Q2 | 18.08 Billion KRW | -6.0% |
| 2021 Q1 | 19.23 Billion KRW | 4.1% |
| 2021 Q4 | 15.73 Billion KRW | -7.78% |
| 2020 FY | 18.47 Billion KRW | -83.06% |
| 2020 Q2 | 210.62 Billion KRW | -0.5% |
| 2020 Q4 | 18.47 Billion KRW | -73.63% |
| 2020 Q3 | 70.08 Billion KRW | -66.73% |
| 2020 Q1 | 211.68 Billion KRW | 94.11% |
| 2019 Q4 | 109.05 Billion KRW | 0.0% |
| 2019 FY | 109.05 Billion KRW | 0.0% |
| 2018 FY | - KRW | 0.0% |
| 2017 FY | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2011 FY | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.03 Billion KRW | -5757.466% |
| Green Cross Holdings Corporation | 1280.16 Billion KRW | 86.092% |
| Green Cross Holdings Corporation | 724.02 Billion KRW | 75.408% |
| Pharmicell Co., Ltd. | 3.02 Billion KRW | -5780.633% |
| Green Cross Corporation | 724.02 Billion KRW | 75.408% |
| GeneOne Life Science, Inc. | 17.15 Billion KRW | -937.613% |
| Celltrion, Inc. | 1890.42 Billion KRW | 90.581% |
| Samsung Biologics Co.,Ltd. | 1909.33 Billion KRW | 90.675% |
| SK bioscience Co.,Ltd. | 20.57 Billion KRW | -765.433% |
| Prestige BioPharma Limited | 89.66 Billion KRW | -98.568% |